CannaWize Editorial
The Research Desk
Clinical trials, systematic reviews, patient-reported outcomes, possible benefits, risks, and the limits that both sales claims and scare headlines leave out.
Browse this section
Find the article you needShowing all 12 articles in this section.
Search the full libraryNew Research Report
New evidence, read with its limits intact.
Latest Research Articles
Updated as evidence, products, and rules change.
High-THC Cannabis Increased Inflammation Without Improving Insulin Sensitivity
A 108-person quasi-randomized trial found a larger acute inflammatory response with higher THC exposure and no measurable improvement in insulin sensitivity.
ResearchLargest US Study Links Teen Cannabis Use to Slower Cognitive Growth
A UC San Diego study of more than 11,000 teens, using hair and saliva testing alongside self-report, found cannabis use linked to slower growth in memory, attention, and processing speed.
ResearchTHC and Dreams: Why Quitting Weed Brings the Rebound
THC suppresses REM sleep and dreaming, and when THC use stops the brain often overshoots into vivid rebound dreaming. Here is what the research shows and does not show.
ResearchCannabinoids and Mental Health: What 54 Randomized Trials Found
A Lancet Psychiatry review found several narrow signals, no broad psychiatric treatment effect, low-certainty evidence, and more adverse events.
ResearchCan Cannabis Ease Opioid Withdrawal? The Evidence Is Early and Uneven
A review of cannabis and opioid withdrawal research, including a 2026 proof-of-concept study, observational findings, THC risks, and evidence from medication treatment.
ResearchCannabinoids for Dementia Agitation: A Signal with Serious Limits
What randomized trials and 2026 meta-analyses say about cannabinoids for agitation in dementia, including effect signals, sedation, heterogeneity, and caregiver questions.
ResearchCannabis for Restless Legs Syndrome: One Small Trial, Many Open Questions
A 2026 open-label trial reported improvement in restless legs syndrome, mostly among people with multiple sclerosis. Here is why the result is promising but not conclusive.
ResearchDo THC Beverages Reduce Alcohol Use? Two Studies Point to a Maybe
A 2026 survey and randomized laboratory study found signs of reduced alcohol use after cannabis beverages or THC, but neither makes THC an alcohol treatment.
ResearchWhy Cancer Survivors Use Cannabis, And What Their Doctors Need to Know
A national survey of cancer survivors found cannabis use for sleep, pain, stress, nausea, and mood. Here is what the survey proves, what it cannot, and why disclosure matters.
ResearchCannabis and Anxiety: Why Dose and Product Matter
A plain-language review of cannabis and anxiety research, including the different evidence for THC and CBD, dose-related risk, and the limits of current trials.
ResearchCannabis and Driving: Impairment Is Not a THC Number
What driving research says about cannabis impairment, why blood THC is difficult to interpret, and how to make a safer transportation plan.
ResearchCannabis and Medication Interactions: A Practical Checklist
How CBD and THC can interact with medicines, why dose and liver metabolism matter, and what information to bring to a pharmacist or clinician.
ResearchCannabis and Sleep: What Research Can, And Cannot, Say
A source-led review of cannabis, CBD, and sleep research, including short-term sedation, insomnia evidence, tolerance, next-day effects, and study limitations.
ResearchCannabis for Chronic Pain: What the 2025 Evidence Shows
A plain-language review of the 2025 AHRQ cannabis and chronic pain evidence, including likely benefits, limits, side effects, and unanswered questions.
Research coverage at CannaWize begins with the exact intervention. Flower, a standardized oral spray, purified CBD, synthetic cannabinoids, and a retail edible cannot be treated as one product. The dose, route, study population, comparison group, and length of follow-up determine what a result can support.
Our reviews look for the size of a benefit, not only whether a result reached statistical significance. They also track adverse effects, withdrawals, uncertainty, and conflicts between studies. Promising evidence is reported as promising, not promoted into a cure.
Clear answers
Frequently Asked Questions
How does CannaWize evaluate cannabis research?
We look at the study design, sample size, comparison group, measured outcome, dose and product used, limitations, and whether the finding has been replicated. We distinguish laboratory findings, observational associations, and randomized clinical evidence instead of treating them as equally conclusive.
Does one study prove that cannabis treats a medical condition?
Usually not. One study can add useful evidence, but treatment conclusions depend on the total body of research, the quality and consistency of results, and guidance from qualified clinicians. We report promising findings without turning them into medical promises.
Why can a patient's experience differ from a study average?
Cannabinoid ratio, dose, route, product consistency, tolerance, other medications, and individual biology can all affect outcomes. Study averages describe groups; they do not guarantee the same benefit or side effect for every person.
Does CannaWize cover risks as well as potential benefits?
Yes. Destigmatizing cannabis requires accuracy, not hype. We cover supported medical uses and harm-reduction information while being transparent about uncertainty, impairment, drug interactions, and populations that may face greater risk.